

IN THE CLAIMS

Please **amend** claims 97 and 98 as follows:

B1 97. (Amended) A composition comprising a pharmaceutically acceptable carrier and a recombinant immunoconjugate which comprises a therapeutic agent or a detectable label bonded to an anti-mesothelin antibody having complementarity-determining regions ("CDRs"), which antibody binds to recombinant mesothelin with a dissociation constant of less than 3×10^{-8} M and which specifically binds to cells expressing mesothelin on their cell surface.

98. (Amended) A kit for detecting mesothelin on the surface of cells, said kit comprising:

(i) an anti-mesothelin antibody having complementarity-determining regions ("CDRs"), which antibody binds to recombinant mesothelin with a dissociation constant of less than 3×10^{-8} M and which specifically binds to cells expressing mesothelin on their cell surface; and

(ii) instructions printed on a tangible medium, said instructions describing the methods of using and uses for said antibody.

Please **add** the following new claims:

B2 99. (New) A composition of claim 97, wherein CDRs of said antibody have 80% or greater sequence similarity to CDRs of SEQ ID NO:5.

100. (New) A composition of claim 97, wherein CDRs of said antibody have 90% or greater sequence similarity to CDRs of SEQ ID NO:5.

101. (New) A composition of claim 97, wherein CDRs of said antibody have an amino acid sequence of CDRs of SEQ ID NO:5.

102. (New) A composition of claim 97, wherein said antibody is an scFv.

103. (New) A composition of claim 97, wherein said antibody has a variable heavy (V_H) region peptide bonded to a variable light (V_L) region through a linker peptide.

104. (New) A composition of claim 97, wherein said antibody has a variable heavy (V_H) encoded by SEQ ID NO:1.

B2
LA
105. (New) A composition of claim 97, wherein said antibody has a variable light (V_L) encoded by SEQ ID NO:1.

106. (New) A composition of claim 97, wherein said antibody is an scFv comprising a variable heavy region and a variable light region as set forth in SEQ ID NO:5.

107. (New) A composition of claim 97, wherein said therapeutic agent is a toxin.

108. (New) A composition of claim 106, wherein said toxin is a modified *Pseudomonas* exotoxin or a cytotoxic fragment thereof.

109. (New) A kit of claim 98, wherein said CDRs of said anti-mesothelin antibody have 80% or greater sequence similarity to CDRs of SEQ ID NO:5.

110. (New) A kit of claim 98, wherein said CDRs of said anti-mesothelin antibody have 90% or greater sequence similarity to CDRs of SEQ ID NO:5.